Abstract：
Schizophrenia is a psychotic disorder and one of the most severe and impactful mental illnesses. Sexual dysfunction is highly prevalent in patients with schizophrenia but remains underdiagnosed and undertreated. Sexual dysfunction is frequently attributed to antipsychotics which may reduce medication adherence, but negative symptoms can also reduce sexual drive.
This review provides an overview of the current knowledge about sexual dysfunction in patients with schizophrenia. The authors first review the literature concerning the mechanisms of sexual dysfunction and explore the impact of antipsychotics on sexual function. Finally, they present the available non-pharmacological and pharmacological treatment strategies for sexual dysfunction in patients with schizophrenia.
Sexual dysfunction in patients with schizophrenia is still underrated by clinicians despite having a negative impact on the quality of life and therapeutic adherence. Antipsychotic treatment is still perceived as a major cause of sexual impairment. Psychiatrists must be aware of this condition and actively question the patients. A comprehensive approach, addressing pharmacological and non-pharmacological aspects, is fundamental for managing sexual dysfunction in schizophrenia. Pharmacological strategies include (1) Serum-level adjustment of the antipsychotic dose, if possible (2) switching to a well-tolerable antipsychotic (aripiprazole, brexpiprazole) and (3) adding a coadjuvant drug (phosphodiesterase-5 inhibitors).
This review provides an overview of the current knowledge about sexual dysfunction in patients with schizophrenia. The authors first review the literature concerning the mechanisms of sexual dysfunction and explore the impact of antipsychotics on sexual function. Finally, they present the available non-pharmacological and pharmacological treatment strategies for sexual dysfunction in patients with schizophrenia.
Sexual dysfunction in patients with schizophrenia is still underrated by clinicians despite having a negative impact on the quality of life and therapeutic adherence. Antipsychotic treatment is still perceived as a major cause of sexual impairment. Psychiatrists must be aware of this condition and actively question the patients. A comprehensive approach, addressing pharmacological and non-pharmacological aspects, is fundamental for managing sexual dysfunction in schizophrenia. Pharmacological strategies include (1) Serum-level adjustment of the antipsychotic dose, if possible (2) switching to a well-tolerable antipsychotic (aripiprazole, brexpiprazole) and (3) adding a coadjuvant drug (phosphodiesterase-5 inhibitors).
摘要：
精神分裂症是一种精神病，是最严重和最具影响力的精神疾病之一。性功能障碍在精神分裂症患者中非常普遍，但仍未得到诊断和治疗。性功能障碍通常归因于抗精神病药，这可能会降低药物依从性。但是阴性症状也会降低性欲。
■这篇综述概述了有关精神分裂症患者性功能障碍的当前知识。作者首先回顾了有关性功能障碍机制的文献，并探讨了抗精神病药物对性功能的影响。最后,他们提出了精神分裂症患者性功能障碍的可用非药物和药物治疗策略.
■精神分裂症患者的性功能障碍仍然被临床医生低估，尽管对生活质量和治疗依从性有负面影响。抗精神病药物治疗仍然被认为是性损害的主要原因。精神科医生必须意识到这种情况并积极询问患者。全面的方法，解决药理学和非药理学方面是治疗精神分裂症性功能障碍的基础。药理学策略包括（1）抗精神病药剂量的血清水平调整，如果可能的话（2）转换为耐受性良好的抗精神病药（阿立哌唑，brexiprazole）和（3）添加辅助药物（磷酸二酯酶-5抑制剂）。
■这篇综述概述了有关精神分裂症患者性功能障碍的当前知识。作者首先回顾了有关性功能障碍机制的文献，并探讨了抗精神病药物对性功能的影响。最后,他们提出了精神分裂症患者性功能障碍的可用非药物和药物治疗策略.
■精神分裂症患者的性功能障碍仍然被临床医生低估，尽管对生活质量和治疗依从性有负面影响。抗精神病药物治疗仍然被认为是性损害的主要原因。精神科医生必须意识到这种情况并积极询问患者。全面的方法，解决药理学和非药理学方面是治疗精神分裂症性功能障碍的基础。药理学策略包括（1）抗精神病药剂量的血清水平调整，如果可能的话（2）转换为耐受性良好的抗精神病药（阿立哌唑，brexiprazole）和（3）添加辅助药物（磷酸二酯酶-5抑制剂）。
